Review



antibodies targeting mlc2a  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Miltenyi Biotec antibodies targeting mlc2a
    Antibodies Targeting Mlc2a, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mlc2a+antibody/pmc12796357-395-15-18?v=Miltenyi+Biotec
    Average 94 stars, based on 9 article reviews
    antibodies targeting mlc2a - by Bioz Stars, 2026-07
    94/100 stars

    Images



    Similar Products

    antibodies targeting mlc2a  (Miltenyi Biotec)
    94
    Miltenyi Biotec antibodies targeting mlc2a
    Antibodies Targeting Mlc2a, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mlc2a+antibody/pmc12796357-395-15-18?v=Miltenyi+Biotec
    Average 94 stars, based on 1 article reviews
    antibodies targeting mlc2a - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    mlc2a antibody  (Miltenyi Biotec)
    94
    Miltenyi Biotec mlc2a antibody
    Mlc2a Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mlc2a+antibody/pmc12410529-30-0-7?v=Miltenyi+Biotec
    Average 94 stars, based on 1 article reviews
    mlc2a antibody - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    immunofluorescence  (Miltenyi Biotec)
    94
    Miltenyi Biotec immunofluorescence
    Immunofluorescence, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mlc2a+antibody/pmc12410529-30-4-7?v=Miltenyi+Biotec
    Average 94 stars, based on 1 article reviews
    immunofluorescence - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    myosin light chain 2a  (Miltenyi Biotec)
    94
    Miltenyi Biotec myosin light chain 2a
    A) Schematic of the protocols used to produce either ventricular CMs or atrial CMs. The ventricular differentiation protocol (referred to as 10B:6A) involves mesoderm induction with 10 ng/mL BMP4 and 6 ng/mL activin A from days 1-3, while the atrial protocol (referred to as <t>4B:2A)</t> involves mesoderm induction using 4 ng/mL BMP4 and 2ng/mL activin A as well as addition of 0.5 µM retinoic acid (RA) from day 3-5. Cells were assessed for mesoderm induction efficiency using PDGFRα and CD56 on day 3. On day 4, ALDH activity and CD235a expression were used to identify second heart field (SHF) and first heart field (FHF) populations. B) Representative mesoderm profile at day 3 and C) day 4 of the differentiation protocol. D) Representative images of aggregate morphology on days 6 and 12 following differentiation with either the ventricular or atrial protocol. E) Representative flow cytometry plots for pan-cardiac marker cTnT and ventricular marker MLC2v in day 20 cultures generated with each differentiation protocol. Quantification of the percentage of cells in each condition expressing F) cTnT + , G) MLC2v, and H) <t>MLC2a.</t> I) Expression of ventricular or atrial genes at day 20 of differentiation. *p<0.05 by two-tailed Student’s t-test.
    Myosin Light Chain 2a, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mlc2a+antibody/bio_rxiv__2025__09__07__674777-79-42-46?v=Miltenyi+Biotec
    Average 94 stars, based on 1 article reviews
    myosin light chain 2a - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    human mouse rat  (Miltenyi Biotec)
    94
    Miltenyi Biotec human mouse rat
    A) Schematic of the protocols used to produce either ventricular CMs or atrial CMs. The ventricular differentiation protocol (referred to as 10B:6A) involves mesoderm induction with 10 ng/mL BMP4 and 6 ng/mL activin A from days 1-3, while the atrial protocol (referred to as <t>4B:2A)</t> involves mesoderm induction using 4 ng/mL BMP4 and 2ng/mL activin A as well as addition of 0.5 µM retinoic acid (RA) from day 3-5. Cells were assessed for mesoderm induction efficiency using PDGFRα and CD56 on day 3. On day 4, ALDH activity and CD235a expression were used to identify second heart field (SHF) and first heart field (FHF) populations. B) Representative mesoderm profile at day 3 and C) day 4 of the differentiation protocol. D) Representative images of aggregate morphology on days 6 and 12 following differentiation with either the ventricular or atrial protocol. E) Representative flow cytometry plots for pan-cardiac marker cTnT and ventricular marker MLC2v in day 20 cultures generated with each differentiation protocol. Quantification of the percentage of cells in each condition expressing F) cTnT + , G) MLC2v, and H) <t>MLC2a.</t> I) Expression of ventricular or atrial genes at day 20 of differentiation. *p<0.05 by two-tailed Student’s t-test.
    Human Mouse Rat, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mlc2a+antibody/pm40482844-625-51-57?v=Miltenyi+Biotec
    Average 94 stars, based on 1 article reviews
    human mouse rat - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    rea398 130 106 141 miltenyi biotec human  (Miltenyi Biotec)
    94
    Miltenyi Biotec rea398 130 106 141 miltenyi biotec human
    A) Schematic of the protocols used to produce either ventricular CMs or atrial CMs. The ventricular differentiation protocol (referred to as 10B:6A) involves mesoderm induction with 10 ng/mL BMP4 and 6 ng/mL activin A from days 1-3, while the atrial protocol (referred to as <t>4B:2A)</t> involves mesoderm induction using 4 ng/mL BMP4 and 2ng/mL activin A as well as addition of 0.5 µM retinoic acid (RA) from day 3-5. Cells were assessed for mesoderm induction efficiency using PDGFRα and CD56 on day 3. On day 4, ALDH activity and CD235a expression were used to identify second heart field (SHF) and first heart field (FHF) populations. B) Representative mesoderm profile at day 3 and C) day 4 of the differentiation protocol. D) Representative images of aggregate morphology on days 6 and 12 following differentiation with either the ventricular or atrial protocol. E) Representative flow cytometry plots for pan-cardiac marker cTnT and ventricular marker MLC2v in day 20 cultures generated with each differentiation protocol. Quantification of the percentage of cells in each condition expressing F) cTnT + , G) MLC2v, and H) <t>MLC2a.</t> I) Expression of ventricular or atrial genes at day 20 of differentiation. *p<0.05 by two-tailed Student’s t-test.
    Rea398 130 106 141 Miltenyi Biotec Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mlc2a+antibody/pm40482844-625-55-57?v=Miltenyi+Biotec
    Average 94 stars, based on 1 article reviews
    rea398 130 106 141 miltenyi biotec human - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    antibodies against mlc2a  (Thermo Fisher)
    90
    Thermo Fisher antibodies against mlc2a
    A) Schematic of the protocols used to produce either ventricular CMs or atrial CMs. The ventricular differentiation protocol (referred to as 10B:6A) involves mesoderm induction with 10 ng/mL BMP4 and 6 ng/mL activin A from days 1-3, while the atrial protocol (referred to as <t>4B:2A)</t> involves mesoderm induction using 4 ng/mL BMP4 and 2ng/mL activin A as well as addition of 0.5 µM retinoic acid (RA) from day 3-5. Cells were assessed for mesoderm induction efficiency using PDGFRα and CD56 on day 3. On day 4, ALDH activity and CD235a expression were used to identify second heart field (SHF) and first heart field (FHF) populations. B) Representative mesoderm profile at day 3 and C) day 4 of the differentiation protocol. D) Representative images of aggregate morphology on days 6 and 12 following differentiation with either the ventricular or atrial protocol. E) Representative flow cytometry plots for pan-cardiac marker cTnT and ventricular marker MLC2v in day 20 cultures generated with each differentiation protocol. Quantification of the percentage of cells in each condition expressing F) cTnT + , G) MLC2v, and H) <t>MLC2a.</t> I) Expression of ventricular or atrial genes at day 20 of differentiation. *p<0.05 by two-tailed Student’s t-test.
    Antibodies Against Mlc2a, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mlc2a+antibody/pm40275010-218-23-26?v=Thermo+Fisher
    Average 90 stars, based on 1 article reviews
    antibodies against mlc2a - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    mlc2a  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology mlc2a
    A) Schematic of the protocols used to produce either ventricular CMs or atrial CMs. The ventricular differentiation protocol (referred to as 10B:6A) involves mesoderm induction with 10 ng/mL BMP4 and 6 ng/mL activin A from days 1-3, while the atrial protocol (referred to as <t>4B:2A)</t> involves mesoderm induction using 4 ng/mL BMP4 and 2ng/mL activin A as well as addition of 0.5 µM retinoic acid (RA) from day 3-5. Cells were assessed for mesoderm induction efficiency using PDGFRα and CD56 on day 3. On day 4, ALDH activity and CD235a expression were used to identify second heart field (SHF) and first heart field (FHF) populations. B) Representative mesoderm profile at day 3 and C) day 4 of the differentiation protocol. D) Representative images of aggregate morphology on days 6 and 12 following differentiation with either the ventricular or atrial protocol. E) Representative flow cytometry plots for pan-cardiac marker cTnT and ventricular marker MLC2v in day 20 cultures generated with each differentiation protocol. Quantification of the percentage of cells in each condition expressing F) cTnT + , G) MLC2v, and H) <t>MLC2a.</t> I) Expression of ventricular or atrial genes at day 20 of differentiation. *p<0.05 by two-tailed Student’s t-test.
    Mlc2a, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mlc2a+antibody/pmc12180709__cir-151-1780-s001-196-5-7?v=Santa+Cruz+Biotechnology
    Average 93 stars, based on 1 article reviews
    mlc2a - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    A) Schematic of the protocols used to produce either ventricular CMs or atrial CMs. The ventricular differentiation protocol (referred to as 10B:6A) involves mesoderm induction with 10 ng/mL BMP4 and 6 ng/mL activin A from days 1-3, while the atrial protocol (referred to as 4B:2A) involves mesoderm induction using 4 ng/mL BMP4 and 2ng/mL activin A as well as addition of 0.5 µM retinoic acid (RA) from day 3-5. Cells were assessed for mesoderm induction efficiency using PDGFRα and CD56 on day 3. On day 4, ALDH activity and CD235a expression were used to identify second heart field (SHF) and first heart field (FHF) populations. B) Representative mesoderm profile at day 3 and C) day 4 of the differentiation protocol. D) Representative images of aggregate morphology on days 6 and 12 following differentiation with either the ventricular or atrial protocol. E) Representative flow cytometry plots for pan-cardiac marker cTnT and ventricular marker MLC2v in day 20 cultures generated with each differentiation protocol. Quantification of the percentage of cells in each condition expressing F) cTnT + , G) MLC2v, and H) MLC2a. I) Expression of ventricular or atrial genes at day 20 of differentiation. *p<0.05 by two-tailed Student’s t-test.

    Journal: bioRxiv

    Article Title: Growth Factor-Based Manufacturing of Human Pluripotent Stem Cell-Derived Cardiomyocytes Using the Vertical Wheel Bioreactor System

    doi: 10.1101/2025.09.07.674777

    Figure Lengend Snippet: A) Schematic of the protocols used to produce either ventricular CMs or atrial CMs. The ventricular differentiation protocol (referred to as 10B:6A) involves mesoderm induction with 10 ng/mL BMP4 and 6 ng/mL activin A from days 1-3, while the atrial protocol (referred to as 4B:2A) involves mesoderm induction using 4 ng/mL BMP4 and 2ng/mL activin A as well as addition of 0.5 µM retinoic acid (RA) from day 3-5. Cells were assessed for mesoderm induction efficiency using PDGFRα and CD56 on day 3. On day 4, ALDH activity and CD235a expression were used to identify second heart field (SHF) and first heart field (FHF) populations. B) Representative mesoderm profile at day 3 and C) day 4 of the differentiation protocol. D) Representative images of aggregate morphology on days 6 and 12 following differentiation with either the ventricular or atrial protocol. E) Representative flow cytometry plots for pan-cardiac marker cTnT and ventricular marker MLC2v in day 20 cultures generated with each differentiation protocol. Quantification of the percentage of cells in each condition expressing F) cTnT + , G) MLC2v, and H) MLC2a. I) Expression of ventricular or atrial genes at day 20 of differentiation. *p<0.05 by two-tailed Student’s t-test.

    Article Snippet: To assess hPSC-CM purity, hPSC-CMs were fixed with 4% (w/v) paraformaldehyde (PFA) for 10 minutes, permeabilized with ice-cold 90% methanol for 20 minutes, and stained with primary antibodies against cardiac troponin T (cTnT, Miltenyi Biotec), myosin light chain-2v (MLC2v, Miltenyi Biotec), and myosin light chain-2a (MLC2a, Miltenyi Biotec) for 30 minutes at room temperature.

    Techniques: Activity Assay, Expressing, Flow Cytometry, Marker, Generated, Two Tailed Test